1-4 of 4
Marja Sankelo
Close
Sort by
Journal Articles

Deep Immune Profiling in Multiple Myeloma at Diagnosis and Under Lenalidomide Maintenance Therapy

Raija Helena Silvennoinen, Komal Kumar Javarappa, Sini Luoma, Philipp Sergeev, Tiina J Öhman, Markku Varjosalo, Pekka Anttila, Marjaana Säily, Anu Partanen, Marja Sankelo, Caroline A. Heckman
Journal: Blood
Blood (2021) 138 (Supplement 1): 1597.
https://doi.org/10.1182/blood-2021-149090
Published: 2021
Journal Articles

A Prospective Phase 2 Study to Assess Minimal Residual Disease after Ixazomib, Lenalidomide and Dexamethasone Treatment for Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

Raija Helena Silvennoinen, MDPhD, Anders Waage, MD PhD, Valdas Peceliunas, MD, Fredrik Schjesvold, MDPhD, Pekka Anttila, MD, Marjaana Säily, MD PhD, Mervi Putkonen, MD PhD, Kristina Carlson, MD, Einar Haukaas, MD, Marja Sankelo, MDPhD, Anu Partanen, MD PhD, Damian L. Szatkowski, MDPhDMSc, Markus Hansson, MD PhD, Anu Marttila, MD, Lucia Ahlberg, MD, Per Axelsson, MD, Birgitta Lauri, MD, Maija Helena Mikkola, MD, Conny Karlsson, MD, Johanna Abelsson, MD, Erik Ahlstrand, MD PhD, Anu Sikiö, MD, Monika Klimkowska, MD PhD, Reda Matuzeviciene, MD PhD, Mona Hoysaeter Fenstad, MD PhD, Sorella Ilveskero, MD PhD, Hareth Nahi, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–41.
https://doi.org/10.1182/blood-2020-138643
Published: 2020
Journal Articles

Carfilzomib, Elotuzumab and Dexamethasone for Relapsed or Refractory Myeloma Patients

Raija Helena Silvennoinen, MDPhD, Hareth Nahi, MD PhD, Pekka Anttila, MD, Perttu Koskenvesa, MD, Juha Lievonen, MD, Anu Marttila, MD, Ville Varmavuo, MD PhD, Anu Sikiö, MD, Marita Nurmi, MD, Marjaana Säily, MD PhD, Anu Partanen, MD PhD, Marja Sankelo, MDPhD, Sini Luoma, MD, Pentti Mäntymaa, MD PhD, Sorella Ilveskero, MD PhD, Henrik Rode Eshoj, PhD, Lene Kongsgaard Nielsen, MD PhD, Esa Jantunen, MD PhD, Caroline A Heckman, PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 20.
https://doi.org/10.1182/blood-2020-138447
Published: 2020
Journal Articles

A Phase 2 Study of Carfilzomib Plus Elotuzumab Plus Dexamethasone for Myeloma Patients Relapsed after 1-3 Prior Treatment Lines

Raija Helena Silvennoinen, MDPhD, Dimitrios Tsallos, BSc(Hons),MSc, Hareth Nahi, MD PhD, Pekka Anttila, MD, Perttu Koskenvesa, MD, Juha Lievonen, MD, Anu Räsänen, MD, Ville Varmavuo, MD PhD, Anu Sikiö, MD, Marita Nurmi, MD, Marjaana Säily, MD PhD, Anu Partanen, MD, Marja Sankelo, MDPhD, Sini Luoma, MD, Sorella Ilveskero, MD PhD, Tarja-Terttu Pelliniemi, MD PhD, Esa Jantunen, MD PhD, Muntasir M Majumder, MSc, BPharm, Samuli Eldfors, PhD, Maija Leppä, MSc(Tech), Caroline A Heckman, PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1975.
https://doi.org/10.1182/blood-2018-99-114593
Published: 2018